Dr. Anthony (Tony) F. Holler

Dr. Holler joined Response Biomedical Corp. as a Director in March 2006. He was one of the original founders of ID Biomedical, and has served as its Director since 1991. Dr. Holler has been the Chairman of CRH Medical Corporation (Formerly Medsurge Medical Products Corp.) since December 2005 and also the Chairman of Trevali Resources Corporation since October 2010.

He serves as Non-Executive Chairman of Q2 Gold Resources Inc. and has been its Director since June 2007. He has been a Director of Neptune Technologies & BioResources, Inc. since July 2011 and as a Director of CRH Medical Corporation since December 2005. Dr. Holler served as Non-Executive Chairman of Corriente Resources Inc. from 2003 to June 2010 and its Director from September 2003. Dr. Holler served as an Emergency physician at University Hospital at University of British Columbia. He is a Member of the British Columbia College of Physicians and Surgeons and received a Bachelor of Science in 1975 and a Medical Degree in 1979 from the University of British Columbia.

Dr. Joseph D. Keegan

Dr. Joseph Keegan joined Response Biomedical Corporation's Board as a Director and Member of the Compensation Committee in June 2011. Dr. Keegan has more than 25 years of experience managing life science tools businesses.

Since joining ForteBio, Inc. in 2007 Dr. Keegan led the Series C financing which raised $25M and established product development and sales strategies that have resulted in compounded annual revenue growth of 45%. During his 9-year tenure at Molecular Devices Corporation, Dr. Keegan grew the company's revenues from $30 million to $190 million through internal growth and acquisitions. In early 2007, he oversaw its acquisition by MDS for $615 million. Dr. Keegan joined MDC from Becton Dickinson and Company where he served as President of Worldwide Tissue Culture and Vice President, General Manager of Worldwide Flow Cytometry. Prior to Becton Dickinson, Dr. Keegan was Vice President of the Microscopy and Scientific Instruments Division of Leica, Inc. He currently serves on the Board of Directors of ALSSA as Chairman, Seahorse Bioscience Inc., Stereotaxis, Inc. (Nasdaq: STXS) and Response Biomedical Corp (RBM:Toronto). Dr. Keegan holds a Ph.D. in Physical Chemistry from Stanford University.

Clinton H. Severson

Mr. Clinton H. Severson joined Response Biomedical Corporation's Board as a Director and Member of the Audit Committee in June 2011. Mr. Severson has been President and Chief Executive Officer of Abaxis Inc. since June 1996.

From February 1989 to May 1996, Mr. Severson served as President and CEO of MAST Immunosystems, Inc. Mr. Severson began his career at Syva from 1978 to 1984, and then moved to 3M Diagnostic Systems from 1984 to 1989. He has been Chairman of the Board of Abaxis Inc. since May 1998 and a Director since June 1996. Mr. Severson has been Non-Executive Director of Trinity Biotech plc since November 2008, a Director of CytoCore, Inc. since November 2006, a Director of IntelliDx, Inc. and as a Director of LXN Corporation since October 2000. Mr. Severson received his Bachelor of Business Administration from Minot State University in 1973.

Lewis J. Shuster

Mr. Lewis Shuster joined Response Biomedical Corporation's Board as a Director and Audit Committee Chairman in June 2011. Currently, he is the Chief Executive Officer of Shuster Capital. From 2003 to 2007, he served as CEO of Kemia Inc., a drug discovery and development company and had previously held executive positions with Invitrogen, including Chief Operating Officer.

From 1994 through to 1999, Mr. Shuster served as Chief Financial Officer and later COO of Pharmacopeia Inc. and also served as EVP, Finance and Operations at Human Genome Sciences from 1992 to 1994. Prior to this he served as EVP and then CEO of Microbiological Associates, where he led a successful turnaround of a failing LBO and built a profitable GLP biological testing service business today known as BioReliance from 1986 until 1992. Before joining Microbiological Associates, he held positions with MDL Ltd. and the Boston Consulting Group. He presently serves as Board Member and Audit Committee Chairman for Complete Genomics, Inc. and MSN Health also serves on the Board of Retrotope, Inc. and is an Entrepreneur in Residence (EIR) with CONNECT in San Diego. Mr. Shuster earned an M.B.A. from Stanford University and a B.A. from Swarthmore College.

Dr. Peter A. Thompson

Peter Thompson, M.D., is currently a Private Equity Partner with OrbiMed who brings over 20 years of industry experience. He co-founded and was CEO of Trubion Pharmaceuticals (NASDAQ: TRBN), co-founded Cleave BioSciences, is an executive of Chiron Corporation and Becton Dickinson and serves as a Director on several public and private company Boards.

Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents, and a board-certified internist and oncologist. He was on staff at the National Cancer Institute following his internal medicine training at Yale University.

Dr. Jonathan Wang

Dr. Jonathan Wang is a Senior Managing Director, Asia at OrbiMed. He has co-founded OrbiMed Asia and is a general partner at its venture capital fund. Previously, he was a Partner at Legend Capital and General Manager at Burrill Greater China Group. He also worked for WI Harper Group and Walden International, two pioneers in the Asia-related VC industry. At WI Harper, he was a Managing Director, overseeing the firm's life sciences activities worldwide.

He was a Board Director at ForteBio, Inc. (acquired by Pall Corporation) and was a co-founder and Board Director at Bridge Laboratories (acquired by Pharmaron Holdings Limited). He is a Board Director at EA, Inc. (formerly Chairman), Response Biomedical Corp. (TSE: RBM) and Bonovo Orthopedics, Inc. He is a co-founder and former Chairman of The BayHelix Group, a premier organization of Chinese life sciences business leaders. He holds a Ph.D. in Molecular Neurobiology from Columbia University, where he obtained scientific training under the supervision of Dr. Eric Kandel, a Nobel Laureate. He was rewarded the Howard Hughes Medical Institute (HHMI) Research Fellowship at Columbia. He also earned an MBA from Stanford University.

Barbara Kinnaird, Ph.D.

Dr. Barbara Kinnaird has over 25 years of research and business experience primarily in the fields of point of care (POC) testing and in vitro diagnostics. Since joining Response Biomedical Corp. in August 2004, Dr. Kinnaird has held several key management positions including responsibilities for Product Development, Quality, Regulatory, Manufacturing and Sales.  Dr. Kinnaird has consistently demonstrated her ability to deliver results from her areas of responsibility.

During Dr. Kinnaird’s tenure in these positions, she has lead teams to improve the product design control, operational efficiencies, gross margins and sales.  Additionally under her direction, the Company obtained and maintain regulatory approvals to support sales in several global jurisdictions such as China, Japan, United States and Canada.  Dr. Kinnaird’s strengths include her extensive experience in empowering a team to manage through organizational changes that improve the Company processes, decrease costs and accelerate business performance.

Dr. Kinnaird holds a Ph.D. in Microbiology and Immunology from the University of British Columbia at the B.C. Children’s Hospital in the Department of Pediatrics. She conducted her post-doctoral research at the Michael Smith Laboratories in genomics and gene expression profiling, in collaboration with the B.C. Genome Sciences Centre and consulted for the Proteomics division of Incyte Genomics Inc.